|Description||Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic activity.|
|Related CAS||934660-93-2 (free base)|
|Synonyms||Methanone, [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]-, (2E)-2-butenedioate (2:1)|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
Trametinib DMSO solvate
Trametinib is a reversible, selective, allosteric MEK1/MEK2 kinase activity inhibitor with IC50 of 0.7 and 0.9 nM for MEK1 and MEK2.
U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.
AZD8330 is an orally active, selective MEK inhibitor with potential antineoplastic activity. AZD8330 specifically inhibits mitogen-activated protein kinase kina...
SMK-17 is a MEK1/2 inhibitor. It can inhibit MEK1 kinase activity in a non-ATP-competitive manner and it is highly selective to MEK1 and 2. SMK-17 can inhibit t...
PD98059 is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding...
PD318088 is a MEK inhibitor
Trametinib is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.
RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK ...
Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic acti...
Selective dual MEK5 kinase inhibitor, with IC50 values of 4.3, 810, 1800, and >6300 nM for MEK5, ERK5, TGFbR1 and other closely related kinases respectively.
cobimetinib, also known as GDC-0973 and XL-518, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1)...
RO5126766, also known as CH5126766, is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-ne...
Binimetinib is an oral, highly selective MEK inhibitor.
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119...
Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated prot...
APS-2-79 is a small molecule antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site, and antagonizes oncogenic Ras signalling (I...
GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated pro...
Selective dual MEK5 and ERK5 (or BMK1) kinase inhibitor, with IC50 values of 1.5, 59, 580 and >6200 nM for MEK5, ERK5, TGFbR1 and other closely related kinases ...
SL327 is a MEK inhibitor. SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion. SL327 had no affect on acquisition, expres...